The stock of Knight Therapeutics Inc (TSE:GUD) is a huge mover today! About 34,095 shares traded hands. Knight Therapeutics Inc (TSE:GUD) has risen 19.97% since March 24, 2016 and is uptrending. It has outperformed by 16.50% the S&P500.
The move comes after 5 months negative chart setup for the $1.19 billion company. It was reported on Oct, 31 by Barchart.com. We have $8.45 PT which if reached, will make TSE:GUD worth $71.40M less.
Knight Therapeutics Inc (TSE:GUD) Ratings Coverage
Out of 2 analysts covering Knight Therapeutics (TSE:GUD), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Knight Therapeutics has been the topic of 2 analyst reports since May 12, 2016 according to StockzIntelligence Inc.
More notable recent Knight Therapeutics Inc (TSE:GUD) news were published by: Seekingalpha.com which released: “How Many Times Can Knight Therapeutics Issue Equity?” on September 22, 2016, also Seekingalpha.com with their article: “Put Knight Therapeutics On Your Watchlist” published on April 01, 2016, Prnewswire.com published: “Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense …” on February 01, 2016. More interesting news about Knight Therapeutics Inc (TSE:GUD) were released by: Businesswire.com and their article: “Antibe Enters into a GUD Product Licensing Agreement with Knight Therapeutics” published on November 16, 2015 as well as Globenewswire.com‘s news article titled: “Advaxis Announces Licensing Agreement With Knight Therapeutics and Raises $25 …” with publication date: August 26, 2015.
Knight Therapeutics Inc is a Canada pharmaceutical company. The company has a market cap of $1.19 billion. The Firm is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It has a 55.24 P/E ratio. It finances other life sciences companies in Canada and internationally.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.